Thermometer, Machine BP, Oximeters is set to be cheaper – News2IN
India

Thermometer, Machine BP, Oximeters is set to be cheaper

Thermometer, Machine BP, Oximeters is set to be cheaper
Written by news2in

New Delhi: The drug price regulator limits the trading margin of five medical devices that are widely used, especially for Covid-19 management, such as pulse oximers, blood pressure monitoring machines, nebulizers, digital thermometers and glucometer at 70%.
This step is expected to result in a significant decline in MRP from these products which are in high demand with many covid patients under the isolation and treatment of houses that require blood pressure monitoring, blood sugar and oxygen regularly, etc.
Data was collected by the authority of the national pharmaceutical price (NPPA) previously margin ranging from up to 709% of the price to the distributor to the MRP level.
The price revised will take effect from July 20 and remains valid until January 31, 2022 or until further orders, which previously, said the regulator.
Regulators request the provisions of the 19st from the drug (price control) in order ‘public interest’ to regulate the price of these five devices under the ‘Trade Margin Rationalization Approach’.
Such medical device manufacturers have been asked to revise their retail price based on prices at the first product sales point or price to the stockist after entering trade margins as closed.
Manufacturers who sell at prices that assume higher trading margins than closed now, will now have to revise prices down and NPPA has asked the manufacturer for the price list and copy to the drug controller and dealer on July 20.
The MRP will be in accordance with the fixed trading margin.
Trade margin is the difference between prices where manufacturers sell devices or products to distributors or stockists and prices paid by the final consumer (MRP).
Every retailer, dealer, hospital and institution must display an additional price list and price list, such as the manufacturer, in a way that is easily accessible by anyone who wants to consult the same, said NPPA.
Any manufacturer does not obey “responsible for depositing an excessive amount along with 15% annual interest from the date of increase in prices other than the penalty of up to 100% of excessive amounts, he said.

About the author

news2in